Posted on Jul 11, 2011
Carmot wins National Institute of Diabetes and Digestive and Kidney Diseases award to discover drugs for metabolic diseases.
San Francisco, CA – July 11, 2011.
Carmot Therapeutics announced today that it has won an SBIR grant from The National Institute of Diabetes and Digestive and Kidney Diseases to discover molecules that selectively inhibit some lipid binding proteins without interfering with other closely related proteins. These studies could lead to new drugs for the treatment of obesity and other metabolic disorders.
The award will fund the application of Carmot’s proprietary Chemotype Evolution technology to discover small molecule inhibitors of fatty acid binding proteins (FABPs), which are important in lipid metabolism and energy storage. Chemotype Evolution is a powerful drug discovery technology that rapidly identifies new lead-like molecules (www.carmot.us). Compared to conventional high-throughput screening, Chemotype Evolution can sample a greater variety of molecular possibilities using much smaller, higher quality chemical libraries.
Specifically, the project will seek small molecules that inhibit FABP4 and FABP5 but do not inhibit other members of the class of FABPs. Animals in which either FABP4 or FABP5 have been genetically knocked out show improvements in a variety of metabolic functions, and when both proteins are eliminated the animals are remarkably resistant to obesity and type 2 diabetes. However, knocking out other members of this family of lipid binding proteins is harmful. Thus, developing selective molecules is essential.
Targeting some members of a protein family without hitting others is a difficult task using traditional methods. Chemotype Evolution is an iterative, innovative approach that is ideally suited for discovering selective next-generation therapeutics.